News Avalo Therapeutics, Inc.

Equities

AVTX

US05338F3064

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-17 pm EDT			5-day change	1st Jan Change
13.62 ^USD	-14.55%		-9.56%	+49.67%

Apr. 17	North American Morning Briefing : Stock Futures -2-	DJ
Apr. 16	Oppenheimer Upgrades Avalo Therapeutics to Outperform From Perform, Price Target is $35	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

North American Morning Briefing : Stock Futures -2-	Apr. 17	DJ
Oppenheimer Upgrades Avalo Therapeutics to Outperform From Perform, Price Target is $35	Apr. 16	MT
Avalo Therapeutics Appoints Biotech Leaders to Board of Directors	Apr. 02	AQ
Avalo Reports 2023 Financial Results and Provides Business Updates	Apr. 01	AQ
Avalo Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 29	CI
Avalo Reports 2023 Financial Results and Provides Business Updates	Mar. 29	AQ
Sector Update: Health Care Stocks Rise Late Afternoon	Mar. 28	MT
Top Midday Gainers	Mar. 28	MT
Wall Street Set to Open Flat in Thursday Trading; Q4 US GDP Revised Up, Weekly Jobless Claims Fall	Mar. 28	MT
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Thursday Ahead of Key Economic Data	Mar. 28	MT
US Futures Little Changed Pre-Bell Thursday Ahead of Raft of Economic Data	Mar. 28	MT
Top Premarket Gainers	Mar. 28	MT
Avalo Therapeutics, Inc. announced that it has received $115.6 million in funding from Deep Track Capital, LP, TCG Crossover Management, LLC, BVF Partners L.P., RA Capital Management, L.P., Commodore Capital LP, Petrichor Holdings, LLC	Mar. 27	CI
Avalo Therapeutics, Inc. acquired AlmataBio, Inc. for $42.5 million.	Mar. 27	CI
Avalo Therapeutics Shares Triple After Acquisition of AlmataBio, Private Placement Financing of Up to $185 Million	Mar. 27	MT
Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 Million	Mar. 27	AQ
Avalo Therapeutics, Inc. Announces Board Appointments	Mar. 27	CI
North American Morning Briefing : Stocks Edge -2-	Mar. 27	DJ
Avalo Therapeutics, Inc. announced that it expects to receive $115.6 million in funding from Deep Track Capital, LP, TCG Crossover Management, LLC, Commodore Capital, BVF Partners L.P., Petrichor Energy Inc., RA Capital Management, L.P.	Mar. 26	CI
Avalo Therapeutics Plans 1-for-240 Reverse Stock Split	Dec. 27	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Avalo Therapeutics, Inc.

Equities

AVTX

US05338F3064

Summary

Filters